Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / in8bio to host investor call at 8 30 am et on tuesda mwn benzinga


INAB - IN8bio to Host Investor Call at 8:30 AM ET on Tuesday December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia | Benzinga

    • Event will follow the presentation of INB-100 data in patients with hematologic malignancies at the American Society of Hematology (ASH) 65th Annual Meeting & Exposition on the evening of December 11, 2023
    • IN8bio's management team will be joined by clinical thought leader Michael Bishop, MD, Director of the David and Etta Jonas Center for Cellular Therapy at The University of Chicago
    • The live webcast can be accessed here

    NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the Company will host a conference call on Tuesday, December 12, 2023 at 8:30 am ET. The event will highlight data presented at the ASH 65th Annual Meeting in a poster presentation on December 11, 2023 starting at 6:00 pm PT. The Company's INB-100 trial is focused on investigating the potential of harnessing donor-derived allogeneic gamma-delta T cells for the treatment of patients with hematological malignancies following hematopoietic bone marrow transplantation (HSCT).

    Speakers on the call will include IN8bio's management team, as well as key oncology thought leader Michael Bishop, MD, Director of the David and Etta Jones Center for Cellular Therapy at the University of Chicago, who will be highlighting gamma-delta T cells as a clinical strategy to prevent relapse of patients with hematological malignancies. Dr. Bishop is a prominent clinical investigator of acute leukemias, with a focus on improving transplant outcomes and preventing relapse. He is a faculty member and a member of the planning committee for the ASTCT/EBMT Conference on Relapse After Transplant and Cellular Therapy. Dr. Bishop previously served as a senior investigator and as the clinical head of stem cell transplantation for the National Cancer Institute (NCI) at the National Institutes of Health.

    Conference Call Details
    IN8bio will host a conference call and webcast on Tuesday, December 12, 2023, at 8:30 am ET to review the updated ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: IN8bio Inc.
    Stock Symbol: INAB
    Market: NASDAQ

    Menu

    INAB INAB Quote INAB Short INAB News INAB Articles INAB Message Board
    Get INAB Alerts

    News, Short Squeeze, Breakout and More Instantly...